In response to stressful events, neonatal mice emit ultrasonic vocalizations (USVs), which are suppressed by BZ agonists. The present study examined the role of the
benzodiazepine/alpha1 (BZ/alpha1) receptor subtype in the suppression engendered by the BZ/alpha1-preferring agonist
zolpidem and the nonselective BZ agonists
triazolam and
diazepam. The role of BZ receptor subtypes was explored further by conducting antagonism studies using the BZ/alpha1-preferring antagonist
beta-carboline-3-carboxylate-t-butyl ester (
beta-CCt), in comparison with the nonselective BZ antagonist
flumazenil. Mouse pups (CFW strain) were separated from their dam and littermates at day 7, and placed for 4 min in a test chamber with reduced ambient temperature (19 +/- 1 degrees C) for recording USVs, motor
incoordination (measured as a pup rolling on its back per grid cross), and body temperature.
Zolpidem,
triazolam, and
diazepam suppressed USVs in a dose-dependent manner, concomitant with increases in
incoordination and augmentation of
hypothermia. These effects of the three BZ agonists were blocked by
flumazenil in a manner consistent with surmountable antagonism. The ability of
zolpidem, but not
triazolam or
diazepam, to suppress USVs and augment
hypothermia was antagonized by
beta-CCt, whereas the increase in motor
incoordination engendered by
zolpidem,
triazolam, and
diazepam was not sensitive to
beta-CCt administration. Collectively, these results suggest that
zolpidem suppresses distress USVs in mouse pups by a mechanism distinct from that of typical BZs. Furthermore, suppression of distress USVs by
zolpidem may involve BZ/alpha1 receptors and a nonanxiolytic mechanism, such as
hypothermia.